|View printer-friendly version|
Aeglea BioTherapeutics Announces Publication of Nonclinical Data on Lead Molecule, AEB1102, in Human Molecular Genetics
Austin, Texas, (September 16, 2015) – Aeglea BioTherapeutics, Inc., a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced publication of nonclinical data on its lead molecule, AEB1102, in Human Molecular Genetics. AEB1102 is an engineered human enzyme designed to degrade arginine, an amino acid, and is being developed to treat cancer and the rare disease arginase I deficiency, which is an inborn error of metabolism leading to toxic levels of arginine in the blood. Study results showed that AEB1102 reduced plasma levels of arginine in a dose-dependent manner in both a neonatal and an adult animal model of arginase I deficiency and that this reduction was sustained with repeated dosing.
"Arginase I deficiency is a serious condition that often causes seizures and intellectual disability, resulting in a significant impact on the quality of life for patients and their caregivers,” said Lindsay C. Burrage, M.D, Ph.D., Assistant Professor, Department of Molecular and Human Genetics, Baylor College of Medicine and lead author of the study. “Elevated arginine levels are thought to contribute to the neurologic features of this disease. However, reducing plasma arginine levels to normal or near-normal levels in patients with arginase I deficiency is challenging with current therapies and thus, new treatment options for these patients are needed.”
“These nonclinical findings further demonstrate the potential of AEB1102 to reduce blood arginine levels and supports the continued development of AEB1102 to treat this rare disease, arginase I deficiency,” said David G. Lowe, Ph.D., co-founder, president and chief executive officer of Aeglea. “Our engineered human enzymes, such as AEB1102, are designed to target specific amino acids in the blood in order to potentially reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of tumors dependent on amino acids by reducing levels below the normal range.”
The publication, titled “Human Recombinant Arginase Enzyme Reduces Plasma Arginine in Mouse Models of Arginase Deficiency” is available at http://hmg.oxfordjournals.org/content/early/2015/09/12/hmg.ddv352.
About Arginase I Deficiency
About Aeglea BioTherapeuticsAeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in oncology with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.
For more information, visit http://aegleabio.com.
# # #
ihttp://www.ncbi.nlm.nih.gov/books/NBK1159/. Accessed August 27, 2015.